Reducing Innate Inflammation in New Onset Type 1 Diabetes
Reducing Innate Inflammation in New Onset Type 1 Diabetes With Lactiplantibacillus Plantarum
Sponsor: Medical College of Wisconsin
Listed as NCT04335656, this PHASE2 trial focuses on Type 1 Diabetes and Type 1 Diabetes Mellitus and remains ongoing. Sponsored by Medical College of Wisconsin, it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
May 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jun 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Jun 2021 — May 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medical College of Wisconsin
For direct contact, visit the study record on ClinicalTrials.gov .